PlainRecalls
FDA Drug Moderate Class II Terminated

Elelyso (taliglucerase alfa) for injection, 200 units/vials,, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017. NDC 0069-0106-01

Reported: March 11, 2020 Initiated: February 27, 2020 #D-0995-2020

Product Description

Elelyso (taliglucerase alfa) for injection, 200 units/vials,, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017. NDC 0069-0106-01

Reason for Recall

Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Details

Recalling Firm
Pfizer Inc.
Units Affected
24,714 vials
Distribution
Nationwide within the United States and Albania, Israel, Serbia, Macedonia, Afghanistan, Botswana/South Africa/Zimbabwe, India, Israel, Rwanda, Uruguay, Mongolia
Location
New York, NY

Frequently Asked Questions

What product was recalled?
Elelyso (taliglucerase alfa) for injection, 200 units/vials,, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017. NDC 0069-0106-01. Recalled by Pfizer Inc.. Units affected: 24,714 vials.
Why was this product recalled?
Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 11, 2020. Severity: Moderate. Recall number: D-0995-2020.